High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics
American Journal of Hematology · 2025
DOI: 10.1002/ajh.27513 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Waseem Lone und 29 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Leukemia and Lymphoma Society.
Abstract (Originalsprache)
High‐grade B‐cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B‐cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and NOS, that demonstrate gene expression profiling (GEP), and genetic signatures similar to BL. Herein, we characterize distinct HGBCL, NOS, cohort ( n = 55) in adults ( n = 45) and in children ( n = 10), and compared the GEP, genomic DNA copy number (CN), and mutational spectrum with de novo DLBCL ( n = 85) and BL ( n = 52). This subgroup, representing ~60% of HGBCL, NOS, lack gene‐expression signature of BL and double hit/dark zone lymphoma, but express DLBCL like signatures and are characterized by either GCB‐ or ABC‐like mRNA signatures and exhibit higher genomic complexity, similar to de novo DLBCL, and show alteration in genes regulating B‐cell activation ( CD79B , MYD88 , PRDM1 , TBLIXR1 , CARD11 ), epigenome ( KMT2D , TET2 ) and cell cycle transition ( TP53 , ASPM ). However, recurrent mutations in genes often mutated in BL (DDX3X, GNA13, CCND3), but rare in DLBCL, are also present in HGBCL‐NOS, highlighting genetic heterogeneity. Consistent with mutation spectrum, frequent genomic CN alterations in genes regulating B‐cell activation (del‐ PRDM1 , gain‐ BCL6 , ‐ REL , ‐ STAT3 ) and cell cycle regulators (del‐ TP53 , del‐ CDKN2A , del‐ RB1 , gain‐ CCND3 ) were observed. Pediatric cases showed GCB‐DLBCL‐like mRNA signatures, but also featured hallmark mutations of pediatric BL. Frequent oncogenic PIM1 mutations were present in adult HGBCL, NOS. In vitro analyses with pharmacologic or genetic inhibition of PIM1 expression triggered B‐cell activation and NF‐κB‐induced apoptosis, suggesting that PIM1 is a rational therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Pathology, University of Miami, Miami, Florida, USA.
- Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
- Cedars-Sinai Medical Center and Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA.
- Department of Pathology, University of Iowa, Iowa City, Iowa, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
ORCID-Profile: Waseem Lone, Xuan Zhang, Tayla B Heavican-Foral
Förderung
- NIH HHS
- NCI NIH HHS
- Leukemia and Lymphoma Society
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Lone, W., Bouska, A., Herek, T. A., Amador, C., Song, J., Xu, A. M., Jochum, D., Issa, I. I., Weisenburger, D. D., Zhang, X., Bhagavathi, S. K., Heavican-Foral, T. B., Sharma, S., Shah, A. R., Mir, A. R., Alkhinji, A. A., El-Gamal, D., Dave, B. J., Hartert, K., …, & Iqbal, J. (2025). High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics. American Journal of Hematology. https://doi.org/10.1002/ajh.27513
Vancouver
Lone W, Bouska A, Herek TA, Amador C, Song J, Xu AM, et al. High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics. American Journal of Hematology. 2025. doi:10.1002/ajh.27513
BibTeX
@article{Lone2025,
author = {Lone, Waseem and Bouska, Alyssa and Herek, Tyler A and Amador, Catalina and Song, Joo and Xu, Alexander M and Jochum, Dylan and Issa, Issa Ismail and Weisenburger, Dennis D and Zhang, Xuan and Bhagavathi, Sharath Kumar and Heavican-Foral, Tayla B and Sharma, Sunandini and Shah, Ab Rauf and Mir, Abdul Rouf and Alkhinji, Aisha Ahmad and El-Gamal, Dalia and Dave, Bhavana J and Hartert, Keenan and Yu, Jiayu and Saumyaranjan, Mallick and Greiner, Timothy C and Vose, Julie and McKeithan, Timothy W and Fu, Kai and Green, Michael and Bi, Chengfeng and Merchant, Akil and Chan, Wing C and Iqbal, Javeed},
title = {High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.27513}
}
EUVIMED